Gyros platform ramps up immunoassay capacity at ICON Development Solutions


Gyros AB, a leader in the automation of miniaturized, immunoassays, confirmed today that ICON Development Solutions, a division of ICON plc, has ramped up its capacity to develop and run immunoassays through the purchase of a third Gyrolab™ workstation.

John Allinson, Vice President Biomarker Lab Services at ICON Development Solutions, explained the reasoning behind the decision: “We are constantly looking for innovative systems that will deliver efficient, high quality and cost-effective bioanalytical services to our clients. Investing in the Gyros™ platform enables us to make significant gains in assay quality, performance and productivity. We can improve the workflows of multiple projects through leveraging a unique, automated, yet open, platform on which we can develop and run many different immunoassays whilst also overcoming many of the challenges associated with conventional immunoassays.” Mr. Allinson continued, “The systems have become almost a ‘one-stop shop’ to meet our immunoassay requirements for some projects whilst complementing other platforms for others. We are also planning to introduce Gyrolab workstations into our US facilities in the near future to enable them to benefit in a similar way”.

Erik Walldén, CEO at Gyros, added: “We are extremely gratified to see that our systems contribute so significantly to the success of CRO’s. ICON is an excellent example of a clearly emerging trend in which forward-thinking contract service organizations strengthen their competitive edge by investing in innovative solutions that better meet their clients’ needs. This trend is particularly strong in the European region where CRO’s are winning contracts from around the world.”

For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: /

Notes to editors:
About Gyros (

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.